Glucose Metabolism in Different PCOS Phenotypes
Associatons of PCOS Phenotypes With Ectopic Lipids, Adipocytokines and Parameters of Insulin Resistance
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women with the polycystic ovary Syndrome defined according to the Rotterdam and the NIH-criteria
- healthy control subjects
Exclusion Criteria:
- BMI>=40kg/m²
- Diagnosis of Diabetes in the PCOS-Group
- Diagnosis of Prediabetes or Diabetes in the control group
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Controls
|
For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
|
|
PCOS-NIH
|
For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
|
|
PCOS-Rotterdam
|
For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of glucose metabolism between PCOS women and healthy control subjects, using data of the OGTT.
Time Frame: Up to 4 weeks
|
In the present study the Glucose metabolism in PCOS women and control subjects was assessed with an OGTT.
Therefore the dynamic levels of glucose, insulin and C-peptide were assessed during an extended OGTT for the calculation of Insulin resistance and beta-cell function.
In addition an 1H-magnetic resonance spectroscopy was done for the assessment of the ectopic lipid content in the liver, heart and the skeletal muscle.
|
Up to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PCOS-1090
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Metabolism Disorders
-
NCT03056677CompletedMetabolism Disorder, Glucose
-
NCT05139264CompletedMetabolism Disorder, Glucose
-
NCT06666933Enrolling by invitationPCOS | IVF Outcome | Glucose Metabolism Disorder
-
NCT07172009RecruitingGlucose Metabolism Disorders (Including Diabetes Mellitus)
-
NCT05176197Active, not recruitingGlucose Intolerance | Glucose Metabolism Disorders (Including Diabetes Mellitus)
-
NCT03162991CompletedPhysical Activity | Sedentary Lifestyle | Metabolism Disorder, Glucose
-
NCT02698878CompletedGlucose Metabolism Disorders | Local Glucose Uptake
-
NCT00349128CompletedDyslipidemia/Glucose Metabolism Disorder
-
NCT06861881Not yet recruitingGlucose Metabolism Disorders (Including Diabetes Mellitus)
Clinical Trials on Oral glucose tolerance test (OGTT)
-
NCT01136902Completed
-
NCT01988987CompletedGlucose Metabolism Disorders | Diabetes Mellitus | Prediabetic State | Diabetes, Gestational
-
NCT02555332CompletedPregnancy | Gestational Diabetes Mellitus | Thyroid Function Tests
-
NCT00897169CompletedDiabetes Mellitus, Type 2 | Diabetes
-
NCT03644238CompletedGestational Diabetes
-
NCT02213276UnknownInflammatory Markers | Glucose Infusion | Bone Markers
-
NCT01371045Withdrawn
-
NCT02520258CompletedGlucose Metabolism Disorder
-
NCT02763267CompletedGestational Diabetes Mellitus